Raymond James & Associates cut its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) by 5.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 110,582 shares of the company’s stock after selling 5,825 shares during the quarter. Raymond James & Associates owned approximately 0.13% of Pediatrix Medical Group worth $1,571,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Eagle Bay Advisors LLC increased its holdings in shares of Pediatrix Medical Group by 149.7% in the 1st quarter. Eagle Bay Advisors LLC now owns 1,823 shares of the company’s stock valued at $27,000 after acquiring an additional 1,093 shares during the last quarter. Ronald Blue Trust Inc. increased its holdings in shares of Pediatrix Medical Group by 94.6% in the 1st quarter. Ronald Blue Trust Inc. now owns 1,938 shares of the company’s stock valued at $29,000 after acquiring an additional 942 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Pediatrix Medical Group by 90.6% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,262 shares of the company’s stock valued at $34,000 after acquiring an additional 1,075 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Pediatrix Medical Group by 97.3% in the 3rd quarter. Royal Bank of Canada now owns 2,166 shares of the company’s stock valued at $35,000 after acquiring an additional 1,068 shares during the last quarter. Finally, Vident Investment Advisory LLC bought a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $149,000. 96.89% of the stock is currently owned by hedge funds and other institutional investors.
Pediatrix Medical Group Trading Down 2.2 %
NYSE:MD opened at $11.21 on Thursday. Pediatrix Medical Group, Inc. has a 12-month low of $11.03 and a 12-month high of $19.63. The firm has a market capitalization of $940.99 million, a P/E ratio of 9.04, a P/E/G ratio of 1.75 and a beta of 1.71. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.24 and a quick ratio of 1.24. The business has a 50 day simple moving average of $12.71 and a 200 day simple moving average of $13.57.
Wall Street Analysts Forecast Growth
MD has been the subject of a number of research analyst reports. StockNews.com initiated coverage on Pediatrix Medical Group in a report on Thursday, October 5th. They issued a “hold” rating for the company. Truist Financial reduced their price objective on Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating for the company in a research report on Wednesday, October 11th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Pediatrix Medical Group presently has a consensus rating of “Hold” and a consensus price target of $16.60.
Pediatrix Medical Group Profile
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
- Five stocks we like better than Pediatrix Medical Group
- 5 Top Rated Dividend Stocks to Consider
- First Solar, an affordable, high-quality green investment
- Why Invest in 5G? How to Invest in 5G Stocks
- 5 Dow stocks to track during the market correction
- What is Forex and How Does it Work?
- Lean on these stocks during GDP expansion
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.